Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...
Catani and colleagues provide data on antigenic properties of neuraminidase proteins of pandemic H1N1 and show that antigenic diversity of the neuraminidase from 2009 to 2020 largely falls into two ...
Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...
Antibody-drug conjugates (ADCs ... Common fixed modifications included C-terminal lysine loss and N-terminal glutamine to pyroglutamate conversion. Common IgG glycans were selected as possible glycans ...
ExtremeTech on MSN15d
Scientists Identify Antibodies That Neutralize the Virus Behind COVID-19The antibodies attach to a part of the virus that doesn't appear to mutate, potentially allowing them to work on multiple COVID-19 variants.
Hosted on MSN19d
Dual Antibodies Found to Combat All SARS-CoV-2 VariantsAnalyzing how these antibodies interacted with the virus, they found one that attaches to a region of the virus that does not mutate often. This area, within the Spike N-terminal domain, or NTD, had ...
RBD-6 and RBD-7 antibodies, on the other hand ... and trimeric spike for SARS-CoV-2 (residues M1–Q1208) and the N-terminal peptidase domain of human ACE2 (residues S19–D615) were expressed using the ...
On the N-terminal, each Siglec has a V-set immunoglobulin (Ig ... The binding of anti-Siglec antibodies or multivalent trans-ligand with inhibitory Siglecs can activate/phosphorylate the ITIMs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback